CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: So similar, yet so different

Cell Death and Differentiation

Volumn 24, Issue 7, 2017, Pages 1172-1183

  Lork, Marie ^a   Verhelst, Kelly ^a   Beyaert, Rudi ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; DEUBIQUITINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; PATTERN RECOGNITION RECEPTOR; POLYUBIQUITIN;

APOPTOSIS; CELL ACTIVATION; CELL DEATH; CONTROLLED CLINICAL TRIAL (TOPIC); GENE ACTIVITY; GENE EXPRESSION; HOMEOSTASIS; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; BIOLOGICAL MODEL; HUMAN; METABOLISM;

ANIMALS; CELL DEATH; DEUBIQUITINATING ENZYMES; HUMANS; MODELS, BIOLOGICAL; NF-KAPPA B; SIGNAL TRANSDUCTION; UBIQUITINATION;

EID: 85016601014     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2017.46     Document Type: Review

References (135)

1. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012; 81: 203-229.
2. Emmerich CH, Ordureau A, Strickson S, Arthur JS, Pedrioli PG, Komander D et al. Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. Proc Natl Acad Sci USA 2013; 110: 15247-15252.
3. Ohtake F, Saeki Y, Ishido S, Kanno J, Tanaka K. The K48-K63 branched ubiquitin chain regulates NF-kappaB signaling. Mol Cell 2016; 64: 251-266.
4. Abdul Rehman SA, Kristariyanto YA, Choi SY, Nkosi PJ, Weidlich S, Labib K et al. MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol Cell 2016; 63: 146-155.
5. Heideker J, Wertz IE. DUBs, the regulation of cell identity and disease. Biochem J 2015; 467: 191.
6. Harhaj EW, Dixit VM. Regulation of NF-kappaB by deubiquitinases. Immunol Rev 2012; 246: 107-124.
7. Saito K, Kigawa T, Koshiba S, Sato K, Matsuo Y, Sakamoto A et al. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma. Structure 2004; 12: 1719-1728.
8. Ritorto MS, Ewan R, Perez-Oliva AB, Knebel A, Buhrlage SJ, Wightman M et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat Commun 2014; 5: 4763.
9. Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A et al. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008; 29: 451-464.
10. Komander D, Reyes-Turcu F, Licchesi JD, Odenwaelder P, Wilkinson KD, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009; 10: 466-473.
11. Sato Y, Goto E, Shibata Y, Kubota Y, Yamagata A, Goto-Ito S et al. Structures of CYLD USP with Met1-or Lys63-linked diubiquitin reveal mechanisms for dual specificity. Nat Struct Mol Biol 2015; 22: 222-229.
12. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797-801.
13. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-805.
14. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793-796.
15. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008; 135: 1311-1323.
16. O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat Cell Biol 2011; 13: 1437-1442.
17. Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS ONE 2013; 8: e76841.
18. Schworer SA, Smirnova II, Kurbatova I, Bagina U, Churova M, Fowler T et al. Toll-like receptor-mediated down-regulation of the deubiquitinase cylindromatosis (CYLD) protects macrophages from necroptosis in wild-derived mice. J Biol Chem 2014; 289: 14422-14433.
19. Legarda D, Justus SJ, Ang RL, Rikhi N, Li W, Moran TM et al. CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by type I IFN. Cell Rep 2016; 15: 2449-2461.
20. Mathis BJ, Lai Y, Qu C, Janicki JS, Cui T. CYLD-mediated signaling and diseases. Curr Drug Targets 2015; 16: 284-294.
21. Sun SC. CYLD: A tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34.
22. Jono H, Lim JH, Chen LF, Xu H, Trompouki E, Pan ZK et al. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 2004; 279: 36171-36174.
23. Ye H, Liu X, Lv M, Wu Y, Kuang S, Gong J et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res 2012; 40: 5201-5214.
24. Reiley W, Zhang M, Wu X, Granger E, Sun SC. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol 2005; 25: 3886-3895.
25. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009; 34: 461-472.
26. Gringhuis SI, Kaptein TM, Wevers BA, Mesman AW, Geijtenbeek TB. Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKKepsilon-And CYLD-dependent Bcl3 activation. Nat Commun 2014; 5: 3898.
27. Thein S, Pham A, Bayer KU, Tao-Cheng JH, Dosemeci A. IKK regulates the deubiquitinase CYLD at the postsynaptic density. Biochem Biophys Res Commun 2014; 450: 550-554.
28. Staal J, Driege Y, Bekaert T, Demeyer A, Muyllaert D, Van Damme P et al. T-cell receptorinduced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J 2011; 30: 1742-1752.
29. Arora M, Kaul D, Varma N, Marwaha RK. Cellular proteolytic modification of tumorsuppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia. Blood Cells Mol Dis 2015; 54: 132-138.
30. Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM et al. MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. Cell Rep 2016; 17: 221-232.
31. Wu X, Fukushima H, North BJ, Nagaoka Y, Nagashima K, Deng F et al. SCFbeta-TRCP regulates osteoclastogenesis via promoting CYLD ubiquitination. Oncotarget 2014; 5: 4211-4221.
32. Kobayashi T, Masoumi KC, Massoumi R. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells. Oncogene 2015; 34: 2251-2260.
33. Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008; 118: 1858-1866.
34. Nagabhushana A, Bansal M, Swarup G. Optineurin is required for CYLD-dependent inhibition of TNFalpha-induced NF-kappaB activation. PLoS ONE 2011; 6: e17477.
35. Ahmed N, Zeng M, Sinha I, Polin L, Wei WZ, Rathinam C et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol 2011; 12: 1176-1183.
36. Takiuchi T, Nakagawa T, Tamiya H, Fujita H, Sasaki Y, Saeki Y et al. Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. Genes Cells 2014; 19: 254-272.
37. Elliott PR, Leske D, Hrdinka M, Bagola K, Fiil BK, McLaughlin SH et al. SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling. Mol Cell 2016; 63: 990-1005.
38. Kupka S, De Miguel D, Draber P, Martino L, Surinova S, Rittinger K et al. SPATA2-mediated binding of CYLD to HOIP enables CYLD recruitment to signaling complexes. Cell Rep 2016; 16: 2271-2280.
39. Schlicher L, Wissler M, Preiss F, Brauns-Schubert P, Jakob C, Dumit V et al. SPATA2 promotes CYLD activity and regulates TNF-induced NF-kappaB signaling and cell death. EMBO Rep 2016; 17: 1485-1497.
40. Wagner SA, Satpathy S, Beli P, Choudhary C. SPATA2 links CYLD to the TNF-Alpha receptor signaling complex and modulates the receptor signaling outcomes. EMBO J 2016; 35: 1868-1884.
41. Draber P, Kupka S, Reichert M, Draberova H, Lafont E, de Miguel D et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep 2015; 13: 2258-2272.
42. Hrdinka M, Fiil BK, Zucca M, Leske D, Bagola K, Yabal M et al. CYLD limits Lys63-And Met1-linked ubiquitin at receptor complexes to regulate innate immune signaling. Cell Rep 2016; 14: 2846-2858.
43. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 2000; 25: 160-165.
44. Massoumi R. CYLD: A deubiquitination enzyme with multiple roles in cancer. Fut Oncol 2011; 7: 285-297.
45. Cleynen I, Vazeille E, Artieda M, Verspaget HW, Szczypiorska M, Bringer MA et al. Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut 2014; 63: 1265-1274.
46. Evans PC, Ovaa H, Hamon M, Kilshaw PJ, Hamm S, Bauer S et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J 2004; 378: 727-734.
47. Komander D, Barford D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem J 2008; 409: 77-85.
48. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C et al. The ubiquitinmodifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-1060.
49. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694-699.
50. Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J et al. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 2015; 528: 370-375.
51. Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE et al. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. Nat Immunol 2008; 9: 254-262.
52. Shembade N, Parvatiyar K, Harhaj NS, Harhaj EW. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J 2009; 28: 513-522.
53. Bosanac I, Wertz IE, Pan B, Yu C, Kusam S, Lam C et al. Ubiquitin binding to A20 ZnF4 is required for modulation of NF-kappaB signaling. Mol Cell 2010; 40: 548-557.
54. Tokunaga F, Nishimasu H, Ishitani R, Goto E, Noguchi T, Mio K et al. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-kappaB regulation. EMBO J 2012; 31: 3856-3870.
55. Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T et al. A20 inhibits LUBAC-mediated NF-kappaB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J 2012; 31: 3845-3855.
56. Catrysse L, Vereecke L, Beyaert R, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol 2014; 35: 22-31.
57. De A, Dainichi T, Rathinam CV, Ghosh S. The deubiquitinase activity of A20 is dispensable for NF-kappaB signaling. EMBO Rep 2014; 15: 775-783.
58. Lu TT, OnizawaM, Hammer GE, Turer EE, Yin Q, Damko E et al. Dimerization and ubiquitin mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity 2013; 38: 896-905.
59. Verhelst K, van Loo G, Beyaert R. A20: Attractive without showing cleavage. EMBO Rep 2014; 15: 734-735.
60. Skaug B, Chen J, Du F, He J, Ma A, Chen ZJ. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol Cell 2011; 44: 559-571.
61. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327: 1135-1139.
62. Opipari AW Jr., Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267: 12424-12427.
63. Verstrepen L, Verhelst K, van Loo G, Carpentier I, Ley SC, Beyaert R. Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem Pharmacol 2010; 80: 2009-2020.
64. Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011; 35: 82-96.
65. Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L et al. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010; 33: 181-191.
66. Daniel S, Patel VI, Shrikhande GV, Scali ST, Ramsey HE, Csizmadia E et al. The universal NF-kappaB inhibitor a20 protects from transplant vasculopathy by differentially affecting apoptosis in endothelial and smooth muscle cells. Transplant Proc 2006; 38: 3225-3227.
67. He KL, Ting AT. A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol Cell Biol 2002; 22: 6034-6045.
68. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009; 137: 721-735.
69. Won M, Park KA, Byun HS, Sohn KC, Kim YR, Jeon J et al. Novel anti-Apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation. Cell Death Differ 2010; 17: 1830-1841.
70. Yamaguchi N, Yamaguchi N. The seventh zinc finger motif of A20 is required for the suppression of TNF-Alpha-induced apoptosis. FEBS Lett 2015; 589: 1369-1375.
71. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R et al. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol 2015; 16: 618-627.
72. Dixit VM, Green S, Sarma V, Holzman LB, Wolf FW, O'Rourke K et al. Tumor necrosis factor-Alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem 1990; 265: 2973-2978.
73. Krikos A, Laherty CD, Dixit VM. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem 1992; 267: 17971-17976.
74. Chanudet E, Huang Y, Ichimura K, Dong G, Hamoudi RA, Radford J et al. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010; 24: 483-487.
75. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 2012; 109: 7865-7870.
76. Balkhi MY, Iwenofu OH, Bakkar N, Ladner KJ, Chandler DS, Houghton PJ et al. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci Signal 2013; 6: ra63.
77. Shrikhande GV, Scali ST, da Silva CG, Damrauer SM, Csizmadia E, Putheti P et al. O-glycosylation regulates ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS ONE 2010; 5: e14240.
78. Hutti JE, Turk BE, Asara JM, Ma A, Cantley LC, Abbott DW. IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway. Mol Cell Biol 2007; 27: 7451-7461.
79. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 2008; 9: 263-271.
80. Duwel M, Welteke V, Oeckinghaus A, Baens M, Kloo B, Ferch U et al. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. J Immunol 2009; 182: 7718-7728.
81. Rodriguez MS, Egana I, Lopitz-Otsoa F, Aillet F, Lopez-Mato MP, Dorronsoro A et al. The RING ubiquitin E3 RNF114 interacts with A20 and modulates NF-kappaB activity and T-cell activation. Cell Death Dis 2014; 5: e1399.
82. Kulathu Y, Garcia FJ, Mevissen TE, Busch M, Arnaudo N, Carroll KS et al. Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nat Commun 2013; 4: 1569.
83. Iha H, Peloponese JM, Verstrepen L, Zapart G, Ikeda F, Smith CD et al. Inflammatory cardiac valvulitis in TAX1BP1-deficient mice through selective NF-kappaB activation. EMBO J 2008; 27: 629-641.
84. Shembade N, Harhaj NS, Liebl DJ, Harhaj EW. Essential role for TAX1BP1 in the termination of TNF-Alpha-, IL-1-And LPS-mediated NF-kappaB and JNK signaling. EMBO J 2007; 26: 3910-3922.
85. Wagner S, Carpentier I, Rogov V, Kreike M, Ikeda F, Lohr F et al. Ubiquitin binding mediates the NF-kappaB inhibitory potential of ABIN proteins. Oncogene 2008; 27: 3739-3745.
86. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP et al. Failure to regulate TNFinduced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289: 2350-2354.
87. Duong BH, Onizawa M, Oses-Prieto JA, Advincula R, Burlingame A, Malynn BA et al. A20 restricts ubiquitination of pro-interleukin-1beta protein complexes and suppresses NLRP3 inflammasome activity. Immunity 2015; 42: 55-67.
88. Vande Walle L, Van Opdenbosch N, Jacques P, Fossoul A, Verheugen E, Vogel P et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 2014; 512: 69-73.
89. Vereecke L, Beyaert R, van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans 2011; 39: 1086-1091.
90. Wang S, Wen F, Tessneer KL, Gaffney PM. TALEN-mediated enhancer knockout influences TNFAIP3 gene expression and mimics a molecular phenotype associated with systemic lupus erythematosus. Genes Immun 2016; 17: 165-170.
91. Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, McGreal NM et al. Africanderived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol 2010; 184: 7001-7009.
92. Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet 2016; 48: 67-73.
93. Takagi M, Ogata S, Ueno H, Yoshida K, Yeh T, Hoshino A et al. Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 2016; S0091-6749: 31286-31286.
94. Zhang F, Yang L, Li Y. The role of A20 in the pathogenesis of lymphocytic malignancy. Cancer Cell Int 2012; 12: 44.
95. Keusekotten K, Elliott PR, Glockner L, Fiil BK, Damgaard RB, Kulathu Y et al. OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. Cell 2013; 153: 1312-1326.
96. Rivkin E, Almeida SM, Ceccarelli DF, Juang YC, MacLean TA, Srikumar T et al. The linear ubiquitin-specific deubiquitinase gumby regulates angiogenesis. Nature 2013; 498: 318-324.
97. Fiil BK, Damgaard RB, Wagner SA, Keusekotten K, Fritsch M, Bekker-Jensen S et al. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol Cell 2013; 50: 818-830.
98. Haas TL, Emmerich CH, Gerlach B, Schmukle AC, Cordier SM, Rieser E et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell 2009; 36: 831-844.
99. Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell 2012; 46: 746-758.
100. Elliott PR, Nielsen SV, Marco-Casanova P, Fiil BK, Keusekotten K, Mailand N et al. Molecular basis and regulation of OTULIN-LUBAC interaction. Mol Cell 2014; 54: 335-348.
101. Schaeffer V, Akutsu M, Olma MH, Gomes LC, Kawasaki M, Dikic I. Binding of OTULIN to the PUB domain of HOIP controls NF-kappaB signaling. Mol Cell 2014; 54: 349-361.
102. Damgaard RB, Walker JA, Marco-Casanova P, Morgan NV, Titheradge HL, Elliott PR et al. The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity. Cell 2016; 166: 1215-1230 e1220.
103. Zhou Q, Yu X, Demirkaya E, Deuitch N, Stone D, Tsai WL et al. Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proc Natl Acad Sci USA 2016; 113: 10127-10132.
104. Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006; 7: 411-417.
105. Chu Y, Soberon V, Glockner L, Beyaert R, Massoumi R, van Loo G et al. A20 and CYLD do not share significant overlapping functions during B cell development and activation. J Immunol 2012; 189: 4437-4443.
106. Jin W, Reiley WR, Lee AJ, Wright A, Wu X, Zhang M et al. Deubiquitinating enzyme CYLD regulates the peripheral development and naive phenotype maintenance of B cells. J Biol Chem 2007; 282: 15884-15893.
107. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
108. Zhang J, Stirling B, Temmerman ST, Ma CA, Fuss IJ, Derry JM et al. Impaired regulation of NF-kappaB and increased susceptibility to colitis-Associated tumorigenesis in CYLD-deficient mice. J Clin Invest 2006; 116: 3042-3049.
109. Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 2007; 204: 1475-1485.
110. Wex K, Schmid U, Just S, Wang X, Wurm R, Naumann M et al. Receptor-interacting protein kinase-2 inhibition by CYLD impairs antibacterial immune responses in macrophages. Front Immunol 2015; 6: 650.
111. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M et al. Regulation of early wave of germ cell apoptosis and spermatogenesis by deubiquitinating enzyme CYLD. Dev Cell 2007; 13: 705-716.
112. Yoshida H, Jono H, Kai H, Li JD. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-Talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280: 41111-41121.
113. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE et al. The ubiquitinediting enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-Triggered signals. Immunity 2008; 28: 381-390.
114. Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R et al. ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem 2006; 281: 18482-18488.
115. Stilo R, Varricchio E, Liguoro D, Leonardi A, Vito P. A20 is a negative regulator of BCL10-And CARMA3-mediated activation of NF-kappaB. J Cell Sci 2008; 121: 1165-1171.
116. Lee AJ, Zhou X, Chang M, Hunzeker J, Bonneau RH, Zhou D et al. Regulation of natural killer T-cell development by deubiquitinase CYLD. EMBO J 2010; 29: 1600-1612.
117. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep 2008; 9: 930-936.
118. Trompouki E, Tsagaratou A, Kosmidis SK, Dolle P, Qian J, Kontoyiannis DL et al. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 2009; 11: 469-476.
119. Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012; 21: 738-750.
120. Jin YJ, Wang S, Cho J, Selim MA, Wright T, Mosialos G et al. Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors. JCI Insight 2016; 1: e86548.
121. Karatzas DN, Xanthopoulos K, Kotantaki P, Pseftogas A, Teliousis K, Hatzivassiliou EG et al. Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-Associated colorectal carcinogenesis-A short report. Cell Oncol (Dordr) 2016; 39: 287-293.
122. Reissig S, Hovelmeyer N, Weigmann B, Nikolaev A, Kalt B, Wunderlich TF et al. The tumor suppressor CYLD controls the function of murine regulatory T cells. J Immunol 2012; 189: 4770-4776.
123. Hovelmeyer N, Wunderlich FT, Massoumi R, Jakobsen CG, Song J, Worns MA et al. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J Exp Med 2007; 204: 2615-2627.
124. Srokowski CC, Masri J, Hovelmeyer N, Krembel AK, Tertilt C, Strand D et al. Naturally occurring short splice variant of CYLD positively regulates dendritic cell function. Blood 2009; 113: 5891-5895.
125. Reissig S, Hovelmeyer N, Tang Y, Weih D, Nikolaev A, Riemann M et al. The deubiquitinating enzyme CYLD regulates the differentiation and maturation of thymic medullary epithelial cells. Immunol Cell Biol 2015; 93: 558-566.
126. Vereecke L, Sze M, Mc Guire C, Rogiers B, Chu Y, Schmidt-Supprian M et al. Enterocytespecific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J Exp Med 2010; 207: 1513-1523.
127. Matmati M, Jacques P, Maelfait J, Verheugen E, Kool M, Sze M et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet 2011; 43: 908-912.
128. Maelfait J, Roose K, Bogaert P, Sze M, Saelens X, Pasparakis M et al. A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection. PLoS Pathog 2012; 8: e1002570.
129. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2011; 12: 1184-1193.
130. Maelfait J, Roose K, Vereecke L, Mc Guire C, Sze M, Schuijs MJ et al. A20 Deficiency in Lung Epithelial Cells Protects against Influenza A Virus Infection. PLoS Pathog 2016; 12: e1005410.
131. Lippens S, Lefebvre S, Gilbert B, Sze M, Devos M, Verhelst K et al. Keratinocyte-specific ablation of the NF-kappaB regulatory protein A20 (TNFAIP3) reveals a role in the control of epidermal homeostasis. Cell Death Differ 2011; 18: 1845-1853.
132. Mc Guire C, Rahman M, Schwaninger M, Beyaert R, van Loo G. The ubiquitin editing enzyme A20 (TNFAIP3) is upregulated during permanent middle cerebral artery occlusion but does not influence disease outcome. Cell Death Dis 2013; 4: e531.
133. Wang X, Deckert M, Xuan NT, Nishanth G, Just S, Waisman A et al. Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-kappaB-And STAT1-dependent chemokine production in astrocytes. Acta Neuropathol 2013; 126: 711-772.
134. Vereecke L, Vieira-Silva S, Billiet T, van Es JH, Mc Guire C, Slowicka K et al. A20 controls intestinal homeostasis through cell-specific activities. Nat Commun 2014; 5: 5103.
135. Drennan MB, Govindarajan S, Verheugen E, Coquet JM, Staal J, McGuire C et al. NKT sublineage specification and survival requires the ubiquitin-modifying enzyme TNFAIP3/A20. J Exp Med 2016; 213: 1973-1981.